Managing Director & Senior Partner
Ben Aylor is a core member of Boston Consulting Group’s Health Care and Operations practice areas. He is BCG's global topic leader on network strategy for pharmaceutical manufacturing and has extensive experience with both strategy and operations projects in the pharmaceuticals industry, including biopharma network designs, operations transformations, make/buy analyses, and sourcing strategies.
Ben’s current focus is on helping clients build their capabilities in new areas—such as digital supply chain—and meet the challenges of major change efforts including post-merger integrations and broad transformations. Ben has led both overall corporate PMI programs and the manufacturing aspects of PMIs.
Before joining the firm, Ben worked at Arthur Andersen Business Consulting.
BCG’s new benchmark reveals that only 10% of companies are truly prepared for supply chain disruptions. Where does your company stand?
Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
Efficiency in supply chain operations shouldn’t come at the expense of flexibility. Here’s how leading companies achieve both.
Acquirers need to plan their integrations carefully and act quickly, but too often they delay decision making and destroy value.
The new administration will fight to advance and protect US economic interests—but America will no longer go it alone.
As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
To address flaws exposed by the pandemic, companies should accelerate efforts to revamp their worldwide manufacturing and sourcing networks—even if that means extra cost.
Even when the global economy fully recovers, the international trade landscape will look dramatically different in the years ahead than it did before the pandemic.
Medtech and biopharma companies can rebound from the current crisis and prepare for an uncertain future.
Plans to tax CO2 emissions that are attributed to imports would hike costs for EU trade partners and redefine competitive advantage in many industries.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.